Lunit Submits 510(k) Application for Image-Based Breast Cancer Risk Prediction Model
Submission marks a key regulatory milestone toward bringing SEER-calibrated, imaging-based risk assessment to U.S. screening programs SEOUL, South Korea, Dec. 8, 2025 /PRNewswire/ -- Lunit (KRX:328130), a leading provider of AI for cancer...
Lunit to Highlight New AI Evidence in Cancer Screening and Breast Density-Driven Risk Modeling at RSNA 2025
Eight oral presentations and six posters demonstrate advances in mammography, DBT performance, and density-informed risk modeling SEOUL, South Korea, Dec. 2, 2025 /PRNewswire/ -- Lunit, a leading provider of AI for cancer diagnostics and precision...
Lunit Surpasses 1 Million Mammograms in U.S. One Year After Volpara Acquisition
Building on Volpara's breast health expertise, Lunit strengthens its U.S. presence—now delivering AI-powered breast cancer screening across 200 imaging sites SEOUL, South Korea, May 19, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider...
SimonMed Imaging Partners with Lunit to Deliver Best-in-Class AI for Breast Cancer Detection
A Major Leap Forward in Patient Health and the Future of Mammography PHOENIX, April 24, 2025 /PRNewswire/ -- SimonMed Imaging®, one of the largest and most advanced outpatient medical imaging providers in the United States, is proud to announce...
Lunit Marks Go-Live in Groundbreaking National AI Cancer Screening Program in BreastScreen NSW
Lunit INSIGHT MMG integrated into the clinical workflow of Australia's BreastScreen New South Wales to assist in reading approximately 31,000 mammography exams annually SEOUL, South Korea, Dec. 9, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a...
Lunit to Showcase Research Contributions at RSNA 2024 with Record-Breaking 20 Abstracts
Twenty studies validate AI performance across diverse populations and clinical settings, including award-winning research in emergency radiology SEOUL, South Korea, Nov. 25, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of...